Clinical Trials Logo

Non-Hodgkin clinical trials

View clinical trials related to Non-Hodgkin.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02559583 Completed - Multiple Myeloma Clinical Trials

Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America

HOLA
Start date: July 2014
Phase: Phase 4
Study type: Observational

The primary purpose of the study is to quantify participants' demographic parameters, country standard therapies, treatment patterns and outcomes among participants with chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) in oncology concentration hospitals in Latin America.

NCT ID: NCT01561911 Completed - Cancer Clinical Trials

A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

Start date: July 2007
Phase: Phase 1
Study type: Interventional

The Purpose of this study is to evaluate the safety and tolerability, and the biological effects of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4, given intravenously, weekly for 4 weeks in the treatment of patients with advanced malignancies refractory to conventional anti-cancer treatment.

NCT ID: NCT00796731 Completed - Lymphoma Clinical Trials

SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma

Start date: October 2008
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the maximum tolerated dose (MTD) of SAR3419 according to the dose limiting toxicities (DLTs) observed when administered as a single agent once weekly. Secondary objectives are: - to characterize the global safety profile - to evaluate the pharmacokinetic (PK) profile of SAR3419 in the proposed dosing schedule - to assess preliminary evidence of anti-lymphoma activity.

NCT ID: NCT00549185 Completed - Lymphoma Clinical Trials

Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma

Start date: October 2007
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the maximum tolerated dose of SAR3419 and to characterize the dose limiting toxicity(ies). Secondary objectives are to determine the anti-lymphoma activity, the global safety and the PK profile.